Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2011

Conditions

Renal Impairment

Interventions

DRUG

Teriflunomide HMR1726

"Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition"

DRUG

Cholestyramine

"Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55"

Trial Locations (1)

Sanofi-Aventis Administrative Office, Berlin